The clinical efficacy of a fixed combination of angiotensin receptor blockers valsartan II with a calcium antagonist amlodipine - drug Exforge® smokers patients with cardiovascular disease and chronic obstructive pulmonary disease

Abstract

The Aim. A study of the clinical efficacy and safety of a fixed combination of valsartan (ARB) with amlodipine (AK), appointed as part of the standard therapy of hypertension and coronary heart disease smoking patients with chronic obstructive pulmonary disease. Material. The study included 36 men aged 40 to 65 years. All patients were treated with statins, aspirin, selective b-blockers; 16.7% of patients received diuretics, and 19.4% - long-acting nitrates. After randomization, patients were divided into 2 groups: group 1 (n=18, mean age 55.8±5.9 years) in addition to those receiving treatment angiotensin-converting enzyme (ACE) and group 2 (n=18, average age 58.0±4.9 years) - combined preparation Eksforzh® (amlodipine 5-10/160 mg valsartan). Study duration - 4 months.Methods. In a study clinical examination wasconducted, bicycle stress test (HEM-test), echocardiography (echocardiography), daily monitoring of blood pressure (BP), spirometry, determination of the concentration of lipids and lipoproteins, glucose, fibrinogen, uric acid, creatinine with calculation of glomerular filtration rate by MDRD.Used questionnaires: Hospital Anxiety and Depression Scale (HADS), St George's Hospital (SGRQ) and quality of life (QOL) SF-36. The Results. The appointment of the drug to patients Eksforzh® accompanied by a significant reduction in levels of “office” in systolic blood pressure at 39.2±9.7 mm Hg. Art. ( p